Prof Lothar Bergmann speaks to ecancer at ESMO 2024 about the results from the SUNNIFORECAST trial. This trial evaluated ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer.

Patients with non-clear-cell renal cell carcinomas were randomly assigned in a 1:1 ratio to receive either nivolumab combined with ipilimumab versus standard of care by investigators choice until disease progression or intolerance occurred.

Prof Bergmann reports that overall survival rate at 12 months was significantly higher with nivolumab plus ipilimumab than with standard of care in non-clear-cell renal cell carcinomas.